FBLN7

Across TCGA pan-cancer cohorts, FBLN7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBLN7 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FBLN7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBLN7 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and LSCC are the cancer types where FBLN7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	27	view →
LUAD	OS	Median	II,III,IV	0.795	1.000	.005	19	view →
LSCC	DFS	Tertile	II,III,IV	0.793	1.000	.008	11	view →
PDAC	DFS	Median	All	0.722	0.871	.043	3	view →
GBM	OS	Median	All	0.279	0.484	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBLN7–CCRCC (DFS)

Open the CCRCC breakdown →